Navigation Links
The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership to Support Phase 3 Development of CPX-351 for AML
Date:7/2/2012

lar study conducted by Celator in newly diagnosed elderly patients with secondary AML supported the initiation of the current Phase 3 program. LLS's TAP supports private sector and academic-based projects with the goal of advancing investigational therapies with high prospects for providing near-term benefit to patients with blood cancers. 

"This is not only welcome funding but also an important vote of confidence in the potential of CPX-351 to improve outcomes for patients with AML from an organization devoted to that goal," said Scott Jackson, chief executive officer, Celator Pharmaceuticals. "Our new agreement extends what has already been a very productive collaboration and we look forward to the day when these efforts  culminate in making a much-needed new treatment option available to patients with AML at large."

About CPX-351
CPX-351 represents a new approach to developing combinations of drugs in which drug molar ratios with synergistic anti-tumor activity are encapsulated in a drug delivery vehicle in order to maintain the desired ratio following administration. CPX-351 has been granted orphan drug status by the FDA for the treatment of AML. CPX-351 is in late-stage clinical development for the treatment of AML. Celator has completed a successful randomized, phase 2 study comparing CPX-351 to the standard "7+3" regimen of cytarabine:daunorubicin in patients 60 years of age up to and including 75 years of age with newly diagnosed AML and has also completed a randomized, phase 2 study of CPX-351 versus intensive salvage therapy in patients 18 years of age up to and including 65 years of age with AML in first relapse. The second study was supported by the original LLS TAP funding.

About Acute Myeloid Leukemia (AML)
The LLS defines AML as a quickly progressing disease in which too many immature white blood cells (not lymphocytes) are found in the blood and bone marrow.  According to LLS, in 2012 approximately 12,950 ne
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics to Host Investor and Analyst Meeting to Discuss Targeted Agents in Myelofibrosis and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia on Sunday, June 3, 2012, in Chicago
2. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
3. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
4. GHX CEO Bruce Johnson Recognized as Ernst & Young Rocky Mountain Region Entrepreneur of the Year 2012
5. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
6. Frost & Sullivan: Next-Generation Sequencing Services is one of the Fastest Growing Markets in the Life Sciences Industry
7. Need for Reduced Healthcare Outlays Creates Strong Growth Potential for Medical Imaging Services, Says Frost & Sullivan
8. 2012 Pharmaceutical Diversification Trends, Egypt & Saudi Arabia Pharmaceutical Markets Analyzed in New Research Reports
9. Updated: LHA Life Sciences & Medical Technologies Virtual Conference
10. LHA Life Sciences & Medical Technologies Virtual Conference
11. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... , Aug. 30, 2014  Boston Scientific ... NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical ... trial investigating vagus nerve stimulation (VNS) for the ... Ph.D., Professor of Therapeutics and Cardiology and Director ... National de la Sante et de la Recherche ...
(Date:8/30/2014)... , Aug. 30, 2014   Royal Philips  ... Affiniti, a new ultrasound system designed to ... demands of increasing patient volumes and cost pressures. Making ... 2014 in Barcelona this ... facing more patients with fewer resources deliver high quality ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research Report ... 2009-2019 is a professional and in-depth market survey ... industry . The report firstly reviews the basic ... application and manufacturing technology. The report then explores ... Scanner listing their product specification, capacity, Production value, ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... Financial Guidance, DUBLIN, Calif., July 1 ... dedicated to the discovery, rapid,development and commercialization ... today commented on the preliminary efficacy,data from ... (decitabine) for,Injection to best supportive care (BSC) ...
... SOUTH EASTON, Mass., July 1 Pressure,BioSciences, Inc. ... scientists,from the New York University ("NYU") School of ... on advances they made in the,areas of breast ... The results were generated in studies using PBI,s ...
Cached Medicine Technology:SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 3SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 4Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies 2Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies 3
(Date:8/30/2014)... Recently, Skmen.com, a well-known clothing manufacturer, has announced its ... the middle of September, all the company’s new and ... to 30 percent off. , As a matter ... carefully made and come with quality guarantees. They can ... is popular for its fashionable, high quality clothes for ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Ticket Down ... Chile exhibition match next Saturday at Levi's Stadium. ... diehard soccer fans in the United States due to the fact ... just about every major city. Many of these games were ... Brazil this past summer. , Levi’s Stadium is a brand new ...
(Date:8/30/2014)... Information supplied by insurance companies has been helping ... consumers in 2014. A group of ratess for term ... open system for adults at http://quotespros.com/life-insurance.html . ... year can help the average person to quote a ... from medical histories. The finder tool works under a ...
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 ... a Spa-on-Wheels which offers the complete spa experience ... inviting lighting and the most important ingredient of ... "the dedicated licensed pro's! People will enjoy the ... continues Kaplan-Pelle. The website reads, "Step into the ...
Breaking Medicine News(10 mins):Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Mexico vs. Chile Tickets at Levi's Stadium in Santa Clara, CA: TicketDown.com Offers Promo Code for Mexico vs. Chile Exhibition Game on September 6th 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2
... leader in all-natural Energy Drinks continues to Fuel the ... Steaz(R), the industry leader in natural energy drinks, ... healthier way to build stamina and sustained energy with ... Shot contains the same ingredients as Steaz,s award-winning ...
... Annual Corporate Philanthropy Summit , LOS ANGELES, Feb. 3 ... its Second Annual Corporate Philanthropy Summit, an event designed ... work with the public and nonprofit sectors to reduce ... be Henry Cisneros, executive chairman of CityView and former ...
... Reality PTSD Combat Simulator -ELK GROVE VILLAGE, Ill., Feb. ... Tammy Duckworth presented the Alexian Brothers Hospital Network with ... February 2, at Alexian Brothers Medical Center, located in ... provide advanced diagnostic and treatment services to Veterans with ...
... nurses, allied healthcare providers, and policymakers will gather ... the Williamsburg Lodge to learn practical, clinical information ... management, and innovative translational research advances that impact ... The full program, faculty, accreditation, and registration information ...
... market for the drug treatment of cancer pain in 2008 ... a report released today by WWMR, Inc. The cancer pain ... continue throughout the next decade. The increasing number of ... value during the forecast period. Few of the many ...
... Grants will fund access to oral health care programs ... PITTSBURGH, Feb. 3 Health studies indicate that oral ... The Highmark Foundation recently awarded $1.9 million in grants ... service region to help improve access to oral health ...
Cached Medicine News:Health News:Steaz Launches Organic, Fair Trade Energy Shot 2Health News:Local Business Leaders Assemble to Address Critical Issues Facing Los Angeles 2Health News:Local Business Leaders Assemble to Address Critical Issues Facing Los Angeles 3Health News:Illinois Department of Veterans' Affairs Presents $97,500 Veteran's Cash Grant to Alexian Brothers Hospital Network 2Health News:Opinion Leaders in Women's Health To Take the Podium at the 17th Annual Congress on Women's Health, March 27-29, 2009 2Health News:Opinion Leaders in Women's Health To Take the Podium at the 17th Annual Congress on Women's Health, March 27-29, 2009 3Health News:US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value 2Health News:US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value 3Health News:Highmark Foundation Awards $1.9 Million to Improve Access to Oral Health and Dental Care for Underserved Populations in Pennsylvania 2Health News:Highmark Foundation Awards $1.9 Million to Improve Access to Oral Health and Dental Care for Underserved Populations in Pennsylvania 3
The MULTI-LINK PIXEL Coronary Stent System was designed to address the challenges of small vessel treatment in patients with abrupt or threatened abrupt closure (ATC)....
FemoStop system is a femoral compression system for hemostasis management. It provides a comfortable and efficient "hands off method of compressing the femoral artery and vein after diagnostic and i...
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
Medicine Products: